Syndax Pharmaceuticals Inc Stock News

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive

WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today anno

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive O

Amphastar and Syndax, two top-rated biotech stocks, topped second-quarter estimates on Tuesday. But shares stayed flat.

Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "

Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "

The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positiv

The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positiv

WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipelin

Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Upgrades Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $0.41 in the fourth quarter, compared to $0.02 in the year-ago quarter. At the moment, the st

Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021.

Syndax’s lead product candidates include SNDX-5613 and SNDX-6352. Click here to read about its growth prospects and my recommendation.

Today's $19 share quote is backed by as much as $7.50 in cash vs. total liabilities under $1 per unit. Larger drug trials are underway testing the usefulness of two cancer-related products.

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.60% to the previous day’s close as strong demand from buyers drove the stock to $16.85. Actively observing the price movement in the last trading, the stock closed the session at $17.48, falling within a range of $16.84 … Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Is An Exciting Stock To Watch. Read More »